YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

This study has been terminated.

First Received: December 3, 2002 Last Updated: March 31, 2006 History of Changes

Sponsor:	Astellas Pharma Inc
Collaborator:	Astellas Pharma US, Inc.
Information provided by:	Astellas Pharma Inc
ClinicalTrials.gov Identifier:	NCT00050297

Purpose

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

Condition	Intervention	Phase
Prostate Cancer	Drug: YM598	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00050297

Locations

Belgium
University Clinic AZ
Brussels, Belgium
University Clinic UCL St. Luc
Brussels, Belgium
Czech Republic
Clinic of Urology, University Hospital
Prague, Czech Republic
Clinic of Urology, University Hospital
Králové, Czech Republic
Clinic of Urology, University Hospital
Olomouc, Czech Republic
Private Urology Out-patient Ward
Jablonec nad Nisou, Czech Republic
France
Hôpital Bichat, service de Urology
Paris, France
Germany
Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
Marburg, Germany
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
Dresden, Germany
Krummbogen 15
Marburg, Germany
Haingasse 22
Bad Homburg, Germany, 61348
Poland
Oncology Center, Department of Urinary Tract Cancer
Warszawa, Poland
Medical University, Clinic of Urology
Wroclaw, Poland
Regional Hospital, Department of Urology
Bydgoszcz, Poland
Bielanski Hospital, Department of Urology
Warszawa, Poland
MedSource Poland
Gdansk, Poland
Spain
Fundacion Hospital Alcorcón, Servicio Urología
Madrid, Spain
Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.
Madrid, Spain
Complejo Hospitaliaro Juan Canalejo, Servicio de Urología
Corunna, Spain
United Kingdom
Department of Urology, Norfolk & Norwich Hospital
Norwich, United Kingdom
Department of Urology, Gartnavel Hospital
Glasgow, United Kingdom
Department of Urology, Taunton & Somerset Hospital
Taunton, United Kingdom
Department of Urology, Bristol Royal Infirmary
Bristol, United Kingdom

Sponsors and Collaborators

Astellas Pharma Inc

Astellas Pharma US, Inc.

More Information

No publications provided

Study ID Numbers:	598-CL-004
Study First Received:	December 3, 2002
Last Updated:	March 31, 2006
ClinicalTrials.gov Identifier:	NCT00050297 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 27, 2009